Effect of Inhaled Nitric Oxide in Acute Chest Syndrome (INOSTA Study)

Last updated: August 1, 2013
Sponsor: Assistance Publique - Hôpitaux de Paris
Overall Status: Completed

Phase

2/3

Condition

Sickle Cell Disease

Red Blood Cell Disorders

Treatment

N/A

Clinical Study ID

NCT00748423
P060701
  • Ages > 18
  • All Genders

Study Summary

Acute chest syndrome (ACS) is a frequent and potentially life-threatening pulmonary illness. It is a complication of sickle cell disease and is the leading cause of death from this disease in adults. Several pathologic processes are recognized causes of ACS, including infectious diseases, hypoventilation secondary to chest pain, in situ thrombosis and pulmonary fat embolism. Inhaled nitric oxide (iNO) has been shown to be a pulmonary vasodilatator with minimal systemic effects and has also been shown to improve gas exchange in both animal and human acute lung injury (ALI).

The combined effects of iNO gas of improving pulmonary ventilation to perfusion matching, reducing alveolar and systemic inflammation, modulate the course of acute chest syndrome, which combine the physiopathology of vaso-occlusive crisis and acute lung injury.

We hypothesise inhaled NO will improve oxygenation and clinical outcome of sickle cell disease patients with acute chest syndrome.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patients with sickle cell disease (Hemoglobin genotypes characterized by standardprocedures as homozygous hemoglobin SS, hemoglobin SC, and S beta thalassemia)

  • Diagnosis of acute chest syndrome based on the presence of fever, dyspnea or chestpain, associated with new pulmonary infiltrates on chest X-ray

Exclusion

Exclusion Criteria:

  • Patient has been hospitalised < 14 days ago

  • Patients presenting with clinically diagnosed bacterial infections

  • Patients who have received an exchange transfusion in the last 30 days or are in atransfusion program.

  • Current pregnancy or lactation

  • Patient who is currently enrolled in any other investigational drug study

  • Previous participation in this study

  • Any of the following medical conditions:

  • Immediate need of ventilatory support wih orotracheal intubation

  • Hemodynamic instability

Study Design

Total Participants: 100
Study Start date:
December 01, 2008
Estimated Completion Date:
December 31, 2012

Study Description

Objectives: To compare the outcome and duration of acute chest syndrome (ACS) in patients with sickle cell disease (SCD) treated with iNO to that of similar episodes experienced by patients which receive a placebo.

Study design: Bi-center, prospective, randomized, controlled clinical trial

  • Enrollment: 24 months

  • Patients will be treated for 72 hours

  • Patients will be followed for 15 days or until discharged home

Sample size:

  • The study will accrue a maximum of 240 patients

  • Progress of the trial will be reviewed by an independent data and safety monitoring committee to determine if randomization should stop for safety reasons.

Connect with a study center

  • Réanimation Médicale, Hôpital A Chenevier-H Mondor

    Creteil, 94 000
    France

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.